Focused On-demand Library for LINE-1 retrotransposable element ORF2 protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O00370

UPID:

LORF2_HUMAN

Alternative names:

Alternative UPACC:

O00370

Background:

The LINE-1 retrotransposable element ORF2 protein is a pivotal enzyme with reverse transcriptase and endonuclease activities. It plays a crucial role in the retrotransposition of the LINE-1 element mRNA, a key process in genomic diversity and evolution. The protein's endonuclease function introduces nicks in chromosomal DNA, facilitating LINE-1 integration. Its unique DNA recognition and cleavage mechanisms, targeting AT-rich regions without bending the DNA helix, underscore its specificity and efficiency in genomic integration.

Therapeutic significance:

Understanding the role of LINE-1 retrotransposable element ORF2 protein could open doors to potential therapeutic strategies. Its intricate involvement in genomic integration and evolution positions it as a key target for exploring novel approaches in gene therapy and the treatment of genetic disorders.